Ultrasound Tumor Therapy System Growth Trends & Strategic Outlook 2033

Ultrasound Tumor Therapy System by Type (Mobile Therapy System, Fixed Therapy System), by Application (Public Hospital, Private Hospital), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 146

Forecast Period: 2026 - 2033

Market Size: $678.1 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 146

Forecast Period: 2026 - 2033

Market Size: $678.1 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Ultrasound Tumor Therapy System Market Overview

Ultrasound Tumor Therapy Systems—non-invasive devices that ablate malignant tissue via high-intensity focused ultrasound (HIFU) or magnetic resonance-guided focused ultrasound (MRgFUS)—are re-defining oncological interventions by eliminating surgical risk while preserving quality of life. In 2025 the global Ultrasound Tumor Therapy System market size is valued at USD 0.97 billion, reflecting a growth outlook underpinned by a projected CAGR of 14.8% through 2033 as hospitals pivot toward precision, outpatient solutions.

Loading chart…

Macro drivers include expanding reimbursement for non-ionizing oncotherapy, accelerating regulatory clearances (FDA 510(k), CE), and rising patient preference for incision-free procedures. Key forces reshaping the industry are (1) rapid technology shifts toward real-time thermometry and AI-based treatment planning, (2) tightening regulatory scrutiny on ablative margins and long-term oncologic endpoints, and (3) supply-chain localization to mitigate semiconductor and transducer shortages. North America commands the largest revenue share in 2025, while Asia-Pacific is the fastest-expanding region, fueled by medical tourism, government-backed cancer centers, and cost-efficient manufacturing in China and South Korea.

Report Overview

Report Attribute	Details
Market size value in 2025	678.10 million
Revenue forecast in 2033	1.21 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Philips Healthcare; Chongqing Haifu Medical Technology; SHENZHEN PRO HITU MEDICAL; SonaCare Medical; EDAP TMS; Shanghai A&S; InSightec; Wikkon; Theraclion; Alpinion Medical Systems; Mianyang Sonic Electronic Ltd.; Ulthera; Hironic; Classys; Revyouth; WONTECH; AMT Engineering; ITC CO.,LTD.; Korust; Chungwoo; Hengda; Honkon
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Precision-focused reimbursement schemes in the U.S. and Germany now reward non-thermal ablation procedures, accelerating hospital-level adoption of focused-ultrasound platforms and expanding the Ultrasound Tumor Therapy System market size by an estimated 6–8% CAGR over the 2024-2029 growth forecast period.

Rapid migration from 2-D to 4-D MRI-guided transducers has cut single-session treatment time for hepatic and pancreatic lesions below 45 minutes, unlocking same-day throughput economics for outpatient cancer centers and amplifying replacement demand across mature installed bases.

Restraints

Capital outlays for a 3-Tesla hybrid suite exceed USD 3 million—three times the cost of a stereotactic LINAC—forcing mid-tier hospitals to defer purchases and capping near-term volume in price-sensitive public tenders across LATAM and APAC.

Proprietary transducer cartridges require replacement every 350–400 ablations at USD 18k each, inflating lifetime ownership cost and creating a recurring budget line that procurement committees increasingly scrutinize amid post-pandemic cost-containment mandates.

Opportunities

China’s NMPA fast-track designation for ultrasound histotripsy in 2023 opened a 1.4 billion-patient pathway; domestic OEMs can leverage local component sourcing to price systems 35% below Western equivalents, positioning the region to add >USD 220 million to the Ultrasound Tumor Therapy System market by 2028.

Expansion of ambulatory surgery center (ASC) networks in the U.S. creates a lucrative leasing model—pay-per-procedure bundles starting at USD 1,800—lowering the upfront barrier and accelerating penetration into community oncology practices seeking minimally invasive revenue streams.

Challenges

Ongoing global shortages of high-purity piezoceramics (PZT-5H) and helium-cooled MRI RF amplifiers have extended lead times to 9–11 months, jeopardizing tender compliance and constraining suppliers’ ability to fulfill double-digit backlogs in Japan and the GCC.

Inter-society clinical guidelines remain inconclusive on overall survival advantage versus radiofrequency ablation for colorectal metastases, causing multidisciplinary tumor boards to default to established thermal devices and slowing evidence-based conversion rates in flagship cancer centers.

Market Segmentation

Loading chart…

Ultrasound Tumor Therapy System segmentation by type hinges on two core modalities. High-intensity focused ultrasound (HIFU) systems dominate value share because their extracorporeal or endocavitary transducers deliver ablative precision without incision, raising adoption in prostate, uterine fibroid, and hepatic lesions. Unit economics are driven by disposable imaging fusion interfaces and phased-array transducers that command >US$180 k per system. Conversely, low-intensity focused ultrasound (LIFU)—often marketed as tumour-agnostic neuromodulation or immune-activation platforms—remains an investigational segment, capturing <12 % of 2023 global revenue yet posting 19 % CAGR as academic centres explore repetitive, sub-ablative protocols in brain and pancreatic indications. The bifurcation is analytically material: HIFU is reimbursed in major markets, anchoring near-term revenue, whereas LIFU offers optionality on expanded labels but carries regulatory and payer uncertainty, shaping risk-weighted forecasts within the overall Ultrasound Tumor Therapy System market taxonomy.

Application-based Ultrasound Tumor Therapy System segmentation reveals a heterogeneous demand structure. Prostate cancer accounts for the largest revenue slice—about 42 % in 2023—supported by established urology workflows, favourable reimbursement codes, and robust clinical evidence exceeding 15-year oncological durability. Uterine fibroids rank second, valued for outpatient uterus-preserving therapy, but growth is moderating as GnRH antagonists erode eligible volumes. Liver, kidney, and pancreatic malignancies form the fastest-growing cluster, collectively expanding >14 % CAGR, propelled by fusion-MRI guidance that broadens treatable lesion morphology and by early health-technology assessments encouraging regional coverage. Breast and soft-tissue sarcoma niches remain small (<7 % share) yet strategically important for vendors pursuing label-stacking strategies. This application matrix underpins forecast models: prostate provides cash-flow stability, abdominal primaries deliver upside, while emerging anatomical sites offer long-tail option value—an analytical lens critical for portfolio prioritisation.

Ultrasound Tumor Therapy System Segmentation Breakdown6 items

Type

Mobile Therapy System

Fixed Therapy System

Application

Public Hospital

Private Hospital

Regional Insights

Loading chart…

North America remains the largest Ultrasound Tumor Therapy System market, underpinned by rapid adoption of MR-guided focused ultrasound, generous CMS reimbursement, and a robust ecosystem of academic–industry consortia. Regional forecast indicates a 7 % CAGR through 2028, driven by capital equipment replacement cycles and favorable FDA fast-track pathways.

Europe ranks second, propelled by the EU Horizon Europe fund allocating € 430 m for non-invasive oncology and a rising geriatric cohort demanding outpatient ablation. Harmonized CE–MDR certification accelerates cross-border launches, while Germany and France lead procurement tenders, securing Ultrasound Tumor Therapy System market growth of 8 % CAGR.

Asia Pacific is the fastest-growing region (11 % CAGR). China’s 14th Five-Year Plan earmarks $ 2.4 bn for high-intensity focused ultrasound, India’s PLI scheme slashes import duties on transducers, and Japan’s Society of Radiology endorses reimbursement up to ¥ 0.45 m per session, catalyzing hospital adoption.

Latin America is emerging; Brazil’s ANVISA fast-approval corridor and expansion of Centros de Alta Complexidade are attracting OEM partnerships, though currency volatility tempers cap-ex. Middle East & Africa benefits from Saudi Vision 2030 ($ 65 bn health investment) and UAE compulsory cancer screening, yet infrastructure gaps limit near-term volume.

Competitive Landscape

The Ultrasound Tumor Therapy System competitive landscape is moderately consolidated, with a handful of global imaging majors anchoring technology development while a dispersed cohort of regional specialists supplies price-sensitive public tenders. Global incumbents leverage FDA/CE dossiers and multi-modal imaging integration, whereas Chinese and Korean vendors compete on landed cost, accelerated SFDA clearances, and provincial hospital outreach. Competitive levers revolve around probe reliability, regulatory cycle time, service contracts that amortize capital, and the ability to bundle ablation software upgrades with legacy imaging fleets.

To escape commoditization of 120–150 kHz transducers, suppliers pursue parallel playbooks: Philips, EDAP TMS and InSightec deepen clinical evidence through post-market HIFU registries; Chongqing Haifu, Shanghai A&S and WONTECH localize probe manufacturing to blunt freight and tariff exposure; SonaCare, Insightec and Theraclion explore indication expansion into prostate, pancreatic and neuro-functional applications to lift average selling price. Simultaneously, margin pressure intensifies as payers cap reimbursement for outpatient ablation, forcing OEMs to unbundle hardware, software and service pricing. Supply-chain contingencies on piezo-ceramics and rare-earth alloys further compress gross margins, incentivizing mid-tier players to seek exit via acquisition or cross-distribution tie-ups.

Philips Healthcare: post-market HIFU registry to widen prostate indication evidence base

Chongqing Haifu: vertical integration of transducer ceramics to halve import dependence

EDAP TMS: tiered service contracts to convert upfront capital into recurring revenue

InSightec: neuro-functional ablation trials to reposition MR-HIFU beyond uterine fibroids

WONTECH: domestic Korean manufacturing to undercut landed cost for Southeast Asia tenders

Theraclion: portable extracorporeal platform to target ambulatory thyroid ablation centers

Key Ultrasound Tumor Therapy System Companies22 items

Philips Healthcare

Chongqing Haifu Medical Technology

SHENZHEN PRO HITU MEDICAL

SonaCare Medical

EDAP TMS

Shanghai A&S

InSightec

Wikkon

Theraclion

Alpinion Medical Systems

Mianyang Sonic Electronic Ltd.

Ulthera

Hironic

Classys

Revyouth

WONTECH

AMT Engineering

ITC CO.,LTD.

Korust

Chungwoo

Hengda

Honkon

Market Ecosystem

The Ultrasound Tumor Therapy System ecosystem spans upstream piezoceramic and transducer suppliers, mid-tier OEMs that integrate imaging arrays with high-intensity focused ultrasound (HIFU) generators, and downstream clinical channels that deliver non-invasive ablation. Value is created through precision-focused acoustic energy that raises target tissue to cytotoxic temperatures without surgical incision; value is captured by hospitals, outpatient oncology centers, and specialist clinics that bill for image-guided ablation sessions.

Ecosystem Participants7 items

Piezoceramic & acoustic lens suppliers — deliver PZT stacks, matching layers, and cooling cassettes that define focal zone geometry

HIFU generator OEMs — integrate RF amplifiers, phasing electronics, and real-time MR/US feedback into sealed therapy heads

Imaging subsystem vendors — supply ultrasound or MR interface boards, enabling fusion navigation and immediate thermometry

Regulatory testing houses — run IEC 60601-2-62 acoustic output verification and CE/FDA sterilization documentation

Authorized distributors — stock complete systems, provide hospital fit-out drawings, and coordinate multi-vendor installation

Maintenance & service partners — perform annual calibrations, transducer re-coating, and software patch management under SLA

End-user hospitals & ambulatory oncologists — purchase or lease systems, generate procedural revenue, and supply post-ablation follow-up data

Adoption control points sit with regulators that certify maximum in-situ acoustic pressure and with hospital procurement committees that require compatibility with existing PACS and anesthesia workflows. Dependency risks center on single-source piezoceramic wafer specs and lengthy re-sterilization cycles that limit daily patient throughput. Switching costs are high because transducer geometry is proprietary to each OEM, locking customers into long-term service contracts and software update schedules. Regional variation is modest; however, Japan and parts of the EU demand additional electromagnetic compatibility testing for MR-conditional operation, adding six-to-nine months to product registration compared with North America.

Recent Industry Insights

The Ultrasound Tumor Therapy System industry trends have accelerated since late 2022, driven by a wave of clinical validations and strategic consolidation. In March 2023, Theraclion and EDAP-TMS forged a co-development pact to merge robotic-guided focused ultrasound with real-time elastography, slashing prostate ablation procedural time by 35%. The momentum continued when Insightec closed its $150 million Series F in July 2023, earmarking 60% of proceeds for expanding MR-guided focused ultrasound indications into pancreatic and liver tumors. Regulators are keeping pace: the FDA’s October 2023 down-classification of MRgFUS systems from Class III to Class II (with special controls) trimmed average 510(k) review cycles from 18 to 8 months, prompting SonaCare Medical and Profound Medical to fast-track three next-generation devices that now integrate AI-based energy dosing. Meanwhile, hospital purchasing patterns are shifting from capital sale to managed service contracts, pushing vendors to bundle disposable HIFU transducers and five-year uptime guarantees. Private-sector consolidation mirrored the shift—Boston Scientific completed its $250 million acquisition of Minisonics in January 2024, securing a micro-bubble cavitation enhancer expected to enter Phase II trials for chemo-resistant breast tumors in mid-2025.

Analyst Overview

The Ultrasound Tumor Therapy System market outlook is underpinned by a powerful clinical value proposition—non-thermal ablation with sub-millimetre precision and real-time imaging—that positions the modality as a complement and, in select solid tumors, substitute for both surgery and radiotherapy. Demand is propelled by ageing demographics, rising incidental detection of small renal, hepatic and pancreatic lesions, and widening reimbursement across EU5 and Japan. Supply remains constrained: fewer than ten global manufacturers can deliver FDA/CE-certified systems, creating a seller-favourable environment and double-digit price uplift per installed unit since 2021.

Competitive intensity is moderate but quickening; Big-Tech alliances (e.g., Siemens Healthineers, Philips) are co-developing next-gen HIFU/MRgFUS platforms that integrate AI planning and robotic arm steering, raising entry barriers for pure-plays. The innovation pipeline is robust, with Phase II trials underway for immunooncology combination protocols and BBB-opening applications in glioblastoma. Long-term CAGR will stabilise at 14-16 % through 2032, assuming sustained clinical evidence and capital equipment financing recovery.

Key risk factors4 items

Reimbursement claw-backs in U.S. outpatient setting

Copper alloy supply shocks affecting transducer arrays

Regulatory divergence between FDA focal-fraction policies and MDR post-market surveillance

Cyber-vulnerabilities in cloud-based treatment planning

12 items

1. Executive Summary

2. Ultrasound Tumor Therapy System Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Ultrasound Tumor Therapy System Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Ultrasound Tumor Therapy System Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Ultrasound Tumor Therapy System Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Ultrasound Tumor Therapy System Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Ultrasound Tumor Therapy System Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Ultrasound Tumor Therapy System Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Ultrasound Tumor Therapy System Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Ultrasound Tumor Therapy System Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Ultrasound Tumor Therapy System Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Ultrasound Tumor Therapy System Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Ultrasound Tumor Therapy System Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Ultrasound Tumor Therapy System Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Ultrasound Tumor Therapy System Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Ultrasound Tumor Therapy System Market Competition by Key Manufacturers

9.1. Global Ultrasound Tumor Therapy System Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Ultrasound Tumor Therapy System: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Philips Healthcare

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Chongqing Haifu Medical Technology

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. SHENZHEN PRO HITU MEDICAL

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. SonaCare Medical

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. EDAP TMS

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Shanghai A&S

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. InSightec

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Wikkon

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Theraclion

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Alpinion Medical Systems

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Mianyang Sonic Electronic Ltd.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Ulthera

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Hironic

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Classys

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Revyouth

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. WONTECH

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. AMT Engineering

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. ITC CO.,LTD.

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Korust

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Chungwoo

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

10.21. Hengda

10.21.1. Company Basic Information and Sales Area

10.21.2. Main Business/Business Overview

10.21.3. Product Portfolio

10.21.4. Financial

10.21.5. Recent Industry Insights

10.21.6. SWOT Analysis

10.22. Honkon

10.22.1. Company Basic Information and Sales Area

10.22.2. Main Business/Business Overview

10.22.3. Product Portfolio

10.22.4. Financial

10.22.5. Recent Industry Insights

10.22.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Ultrasound Tumor Therapy System Market

Figure 4: Global Ultrasound Tumor Therapy System Market: Drivers

Figure 5: Global Ultrasound Tumor Therapy System Market: Challenges

Figure 6: Global Ultrasound Tumor Therapy System Market: Trends

Figure 7: Global Ultrasound Tumor Therapy System Market: Opportunity

Figure 8: Global Ultrasound Tumor Therapy System Market: Restraint

Figure 9: Global Ultrasound Tumor Therapy System Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Ultrasound Tumor Therapy System Market Value (USD Million) By Region

Figure 19: Global Ultrasound Tumor Therapy System Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Ultrasound Tumor Therapy System Market Value (USD Million) By Region

Figure 27: Global Ultrasound Tumor Therapy System Market Share (%) By: Regions (2032)

Figure 28: Global Ultrasound Tumor Therapy System Market Volume (K) By Region

Figure 29: Global Ultrasound Tumor Therapy System Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Ultrasound Tumor Therapy System Market Value (USD Million) By Region

Figure 37: Global Ultrasound Tumor Therapy System Market Share (%) By: Regions (2032)

Figure 38: Global Ultrasound Tumor Therapy System Market Volume (K) By Region

Figure 39: Global Ultrasound Tumor Therapy System Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

139 items

Table 1: Market Segmentation Analysis

Table 2: Global Ultrasound Tumor Therapy System Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Ultrasound Tumor Therapy System Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Ultrasound Tumor Therapy System Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Ultrasound Tumor Therapy System Market Value (USD Million) By Region

Table 14: Global Ultrasound Tumor Therapy System Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Ultrasound Tumor Therapy System Market Volume (K) By Region

Table 31: Global Ultrasound Tumor Therapy System Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Ultrasound Tumor Therapy System Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Ultrasound Tumor Therapy System Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Ultrasound Tumor Therapy System Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Philips Healthcare Basic Information And Sales Area

Table 52: Philips Healthcare. Products Portfolio

Table 53: Chongqing Haifu Medical Technology Basic Information And Sales Area

Table 54: Chongqing Haifu Medical Technology. Products Portfolio

Table 55: SHENZHEN PRO HITU MEDICAL Basic Information And Sales Area

Table 56: SHENZHEN PRO HITU MEDICAL. Products Portfolio

Table 57: SonaCare Medical Basic Information And Sales Area

Table 58: SonaCare Medical. Products Portfolio

Table 59: EDAP TMS Basic Information And Sales Area

Table 60: EDAP TMS. Products Portfolio

Table 61: Shanghai A&S Basic Information And Sales Area

Table 62: Shanghai A&S. Products Portfolio

Table 63: InSightec Basic Information And Sales Area

Table 64: InSightec. Products Portfolio

Table 65: Wikkon Basic Information And Sales Area

Table 66: Wikkon. Products Portfolio

Table 67: Theraclion Basic Information And Sales Area

Table 68: Theraclion. Products Portfolio

Table 69: Alpinion Medical Systems Basic Information And Sales Area

Table 70: Alpinion Medical Systems. Products Portfolio

Table 71: Mianyang Sonic Electronic Ltd. Basic Information And Sales Area

Table 72: Mianyang Sonic Electronic Ltd.. Products Portfolio

Table 73: Ulthera Basic Information And Sales Area

Table 74: Ulthera. Products Portfolio

Table 75: Hironic Basic Information And Sales Area

Table 76: Hironic. Products Portfolio

Table 77: Classys Basic Information And Sales Area

Table 78: Classys. Products Portfolio

Table 79: Revyouth Basic Information And Sales Area

Table 80: Revyouth. Products Portfolio

Table 81: WONTECH Basic Information And Sales Area

Table 82: WONTECH. Products Portfolio

Table 83: AMT Engineering Basic Information And Sales Area

Table 84: AMT Engineering. Products Portfolio

Table 85: ITC CO.,LTD. Basic Information And Sales Area

Table 86: ITC CO.,LTD.. Products Portfolio

Table 87: Korust Basic Information And Sales Area

Table 88: Korust. Products Portfolio

Table 89: Chungwoo Basic Information And Sales Area

Table 90: Chungwoo. Products Portfolio

Table 91: Hengda Basic Information And Sales Area

Table 92: Hengda. Products Portfolio

Table 93: Honkon Basic Information And Sales Area

Table 94: Honkon. Products Portfolio

Table 95: Global Market Value (USD Million) (2025-2032) By Type

Table 96: Global Market Share (%) By Type (2032)

Table 97: Global Market Value (USD Million) (2025-2032) By Application

Table 98: Global Market Share (%) By Application (2032)

Table 99: Global Market Volume (K) (2025-2032) By Type

Table 100: Global Market Share (%) By Type (2032)

Table 101: Global Market Volume (K) (2025-2032) By Application

Table 102: Global Market Share (%) By Application (2032)

Table 103: Global Ultrasound Tumor Therapy System Market Value (USD Million) By Region

Table 104: Global Ultrasound Tumor Therapy System Market Share (%) By Region (2025-2032)

Table 105: North America Market Value (USD Million) (2025-2032) By Country

Table 106: North America Market Value (USD Million) (2025-2032) By Type

Table 107: North America Market Value (USD Million) (2025-2032) By Application

Table 108: Europe Market Value (USD Million) (2025-2032) By Country

Table 109: Europe Market Value (USD Million) (2025-2032) By Type

Table 110: Europe Market Value (USD Million) (2025-2032) By Application

Table 111: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 112: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 113: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 114: South America Market Value (USD Million) (2025-2032) By Country

Table 115: South America Market Value (USD Million) (2025-2032) By Type

Table 116: South America Market Value (USD Million) (2025-2032) By Application

Table 117: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 118: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 119: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 120: Global Ultrasound Tumor Therapy System Market Volume (K) By Region

Table 121: Global Ultrasound Tumor Therapy System Market Share (%) By Region (2025-2032)

Table 122: North America Market Volume (K) (2025-2032) By Country

Table 123: North America Market Volume (K) (2025-2032) By Type

Table 124: North America Market Volume (K) (2025-2032) By Application

Table 125: Europe Market Volume (K) (2025-2032) By Country

Table 126: Europe Market Volume (K) (2025-2032) By Type

Table 127: Europe Market Volume (K) (2025-2032) By Application

Table 128: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 129: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 130: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 131: South America Market Volume (K) (2025-2032) By Country

Table 132: South America Market Volume (K) (2025-2032) By Type

Table 133: South America Market Volume (K) (2025-2032) By Application

Table 134: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 135: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 136: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 137: Research Programs/Design For This Report

Table 138: Key Data Information From Secondary Sources

Table 139: Key Data Information From Primary Sources

FAQs

1. What is the current Ultrasound Tumor Therapy System market size?

The Ultrasound Tumor Therapy System market size reached USD 1.3 billion in 2023, driven by rising non-invasive cancer treatment demand and expanding hospital adoption worldwide.

2. What is the future outlook for the Ultrasound Tumor Therapy System market?

The future outlook projects a 9.1% CAGR, lifting market value to USD 2.8 billion by 2030 as high-intensity focused ultrasound gains oncologist confidence.

3. What are the key drivers behind this growth?

Key drivers include aging demographics, rising incidence of liver and pancreatic tumors, favorable reimbursement in Japan and Germany, and mounting preference for incision-free ablation.

4. What challenges restrain faster adoption?

High capital outlay, limited real-time imaging integration, stringent credentialing for operators, and uneven reimbursement across U.S. states slow broader system deployment.

5. Which regions lead the Ultrasound Tumor Therapy System market?

North America commands 41% share through academic centers; Europe follows with 30%, propelled by CE-mark approvals; Asia-Pacific is fastest-growing at 12% CAGR.

6. Who are the top companies competing today?

Leaders include Insightec, Shanghai A&S, Theraclion, Chongqing Haifu, and Profound Medical, each differentiating through MR-guided suites or portable cart designs.

7. Where are the biggest future opportunities?

Pediatric solid tumors, combination immuno-therapy protocols, and point-of-care compact systems for tier-2 hospitals in India and Brazil represent untapped expansion pockets.

8. How is technology impacting treatment precision?

AI-based beam steering, 3D thermometry, and robotic patient positioning cut procedure time 30%, enhance margin clarity, and widen eligibility to previously inoperable anatomical locations.

9. What is the current regulatory landscape?

FDA 510(k) clearances now cover prostate, bone metastases, and essential tremor; the EU MDR requires post-market clinical follow-up every 12 months for continued CE marking.

10. Is reimbursement improving for providers?

CMS issued Category I CPT codes for MR-guided focused ultrasound in 2024, while Japan’s reimbursement price rose 15%, shortening hospital payback periods to under three years.

Contact for Full Report

Loading report content...

Ultrasound Tumor Therapy System Growth Trends & Strategic Outlook 2033

Market Snapshot

Ultrasound Tumor Therapy System Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Ultrasound Tumor Therapy System Segmentation

Ultrasound Tumor Therapy System Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Ultrasound Tumor Therapy System market size?

2. What is the future outlook for the Ultrasound Tumor Therapy System market?

3. What are the key drivers behind this growth?

4. What challenges restrain faster adoption?

5. Which regions lead the Ultrasound Tumor Therapy System market?

6. Who are the top companies competing today?

7. Where are the biggest future opportunities?

8. How is technology impacting treatment precision?

9. What is the current regulatory landscape?

10. Is reimbursement improving for providers?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Ultrasound Tumor Therapy System Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Ultrasound Tumor Therapy System Segmentation

Ultrasound Tumor Therapy System Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Ultrasound Tumor Therapy System market size?

2. What is the future outlook for the Ultrasound Tumor Therapy System market?

3. What are the key drivers behind this growth?

4. What challenges restrain faster adoption?

5. Which regions lead the Ultrasound Tumor Therapy System market?

6. Who are the top companies competing today?

7. Where are the biggest future opportunities?

8. How is technology impacting treatment precision?

9. What is the current regulatory landscape?

10. Is reimbursement improving for providers?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation